pioglitazone and Sleep Apnea, Obstructive studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)

Research Excerpts

Excerpt	Relevance	Reference
"Pioglitazone administration increased insulin sensitivity in otherwise untreated individuals with OSA, without any change in polysomnographic sleep measures over an eight-week period."	5.22	Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study. ( Abbasi, F; Ariel, D; Cardell, J; Grove, K; Kim, SH; Kushida, CA; Lamendola, C; Liu, A; Mojaddidi, H; Patel, S; Reaven, GM; Tomasso, V; Tsao, PS; Xu, S, 2016)
" Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA."	3.85	Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea. ( Abbasi, F; Ariel, D; Cardell, J; Grove, K; Kim, SH; Kushida, CA; Lamendola, C; Liu, A; Mojaddidi, H; Patel, S; Reaven, GM; Tomasso, V; Tsao, PS; Xu, S, 2017)

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Liu, A	2
Kim, SH	2
Ariel, D	2
Abbasi, F	2
Lamendola, C	2
Cardell, J	2
Xu, S	2
Patel, S	2
Tomasso, V	2
Mojaddidi, H	2
Grove, K	2
Tsao, PS	2
Kushida, CA	2
Reaven, GM	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
Interfacing Adiposity, Sleep Apnea, and Insulin Resistance[NCT02192684]		45 participants (Actual)	Interventional	2010-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA. (NCT02192684)
Timeframe: 8 weeks

Intervention	AHI events/hour (Median)
Pioglitazone	35.8
Placebo	34.4

pioglitazone and Sleep Apnea, Obstructive